Summary of MediWound Ltd. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 Revenue: $1.9 million, down from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to the U.S. government shutdown.

Gross Profit: $300,000 (14.9% of revenue) compared to $900,000 (15.5%) in the prior year.

R&D Expenses: Increased to $4.5 million from $3.0 million, reflecting ongoing investment in the EscharEx VALUE Phase III study.

SG&A Expenses: Decreased to $3.6 million from $4.0 million, mainly due to lower marketing and share-based compensation expenses.

Operating Loss: $7.8 million, up from $6.1 million in Q4 2024.

Net Loss: $7.2 million ($0.56 per share), compared to $3.9 million ($0.36 per share) in the prior year.

Full Year Revenue: $17.0 million, down from $20.2 million in 2024, attributed to the government shutdown and lower product sales to Vericel.

Full Year Net Loss: $23.9 million ($2.10 per share), improved from a net loss of $30.2 million ($3.30 per share) in 2024.

Cash Position: $53.6 million as of December 31, 2025, up from $43.6 million at the end of 2024.

2Strategic Updates and Business Highlights

EscharEx Development: Enrollment is ongoing in the Phase III VALUE study for venous leg ulcers (VLUs), with plans to expand into diabetic foot ulcers (DFUs) and pressure ulcers in 2026.

NexoBrid Manufacturing: The expanded facility is operational, increasing production capacity sixfold, pending regulatory approvals expected in 2026.

Collaborations: New partnerships with B. Braun and existing collaborations with companies like Coloplast and ConvaTec enhance the clinical development of EscharEx.

Clinical Evidence: Positive real-world data supports NexoBrid's efficacy in severe burn treatment, particularly in military settings.

3Forward Guidance and Outlook

Revenue Guidance for 2026: $24 million to $26 million, with expectations for continued support from BARDA and the U.S. Department of War.

Long-term Revenue Projections: $32 million to $35 million for 2027 and $50 million to $55 million for 2028, contingent on regulatory approvals and successful clinical outcomes.

4Challenges and Points of Concern

Revenue Decline: Significant drop in Q4 and full-year revenue compared to prior periods, primarily due to the U.S. government shutdown affecting contract initiation.

Operating Losses: Continued operating losses and increased R&D spending may raise concerns about financial sustainability if revenue does not ramp up as projected.

Regulatory Risks: Dependence on timely regulatory approvals for expanded manufacturing and new product indications poses a risk to achieving revenue targets.

5Notable Q&A Insights

Manufacturing Demand: High demand for NexoBrid is anticipated post-regulatory approval, but current production is limited.

Pressure Ulcer Study: The upcoming investigator-led study for pressure ulcers is expected to unlock additional market potential, though initial sales forecasts do not include this indication.

BARDA Funding: Clarification on revenue guidance indicates that initial BARDA revenues are expected to start in Q2 2026, following contract finalization.

Interim Analysis: The VALUE trial's interim analysis will assess the need for sample size adjustments, which could impact timelines and costs. Overall, while MediWound Ltd. has made significant strides in clinical development and manufacturing capacity, it faces challenges related to revenue generation and regulatory dependencies that could impact its financial outlook.